Recent H1’s highlighted ongoing licensing discussions for multiple products. In our view, MED2002 (topical treatment for Erectile Dysfunction) in particular is a differentiated product with significant potential in both prescription and OTC markets, and the revised trial schedule further de-risks the programme. We look forward to PK data followed by Phase III start in H1 2018.
22 Sep 2017
N+1 Singer - Futura Medical - All set for MED2002 Phase III trial start in H1 2018
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
N+1 Singer - Futura Medical - All set for MED2002 Phase III trial start in H1 2018
Futura Medical plc (FUM:LON) | 35.5 -0.4 (-2.7%) | Mkt Cap: 107.0m
- Published:
22 Sep 2017 -
Author:
Dr Jens Lindqvist -
Pages:
4
Recent H1’s highlighted ongoing licensing discussions for multiple products. In our view, MED2002 (topical treatment for Erectile Dysfunction) in particular is a differentiated product with significant potential in both prescription and OTC markets, and the revised trial schedule further de-risks the programme. We look forward to PK data followed by Phase III start in H1 2018.